Aravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019 Annual Meeti
Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy
May 28, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present additional data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress taking place June 1 – 5 in Lisbon, Portugal. PVX108 is a peptide-based immunotherapy designed to safely induce immune tolerance to peanut allergens without the safety limitations of other approaches that expose patients to intact, allergenic protein that may cause allergic reactions or anaphylaxis during treatment.
Sara Prickett, BSc, PhD, Chief Scientific Officer at Aravax will present the data in an oral presentation titled: “PVX108 – A Peptide-Immunotherapy for Peanut Allergy Shows Exceptional Safety in Peanut-Allergic Adults (Abstract #2071) during Session LB OAS 03 (Advances in cellular immunology) at 15.30 on Tuesday 4 June 2019, in Hall 14.